Soluble syndecan-1 modulates myeloma growth but not through FGF signalling

被引：0
|
作者：
Lovell, RA
Guimond, SE
Turnbull, JE
Moss, PAH
Pratt, G
机构：
[1] Birmingham Heartlands & Solihull NHS Trust, Birmingham, W Midlands, England
[2] Univ Birmingham, Inst Canc Studies, Birmingham, W Midlands, England
[3] Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2004年 / 125卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
28
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [31] Serum levels of soluble syndecan-1 in Hodgkin's lymphoma
    Vassilakopoulos, TP
    Kyrtsonis, MC
    Papadogiannis, A
    Nadali, G
    Angelopoulou, MK
    Tzenou, T
    Dimopoulou, MN
    Siakantaris, MP
    Kontopidou, FN
    Kalpadakis, C
    Kokoris, SI
    Dimitriadou, EM
    Tsaftaridis, P
    Pizzolo, G
    Pangalis, GA
    ANTICANCER RESEARCH, 2005, 25 (6C) : 4743 - 4746
  • [32] Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions
    Bayer-Garner, IB
    Sanderson, RD
    Dhodapkar, MV
    Owens, RB
    Wilson, CS
    MODERN PATHOLOGY, 2001, 14 (10) : 1052 - 1058
  • [33] Syndecan-1 is essential for the myeloma cell growth factor activity of EGF-family ligands in multiple myeloma.
    Mahtouk, K
    Cremer, FW
    Rème, T
    Jourdan, M
    Baudard, M
    Moreaux, M
    Requirand, G
    Fiol, G
    De Vos, J
    Moos, M
    Quittet, P
    Goldschmidt, H
    Rossi, JF
    Hose, D
    Klein, B
    BLOOD, 2005, 106 (11) : 186A - 186A
  • [34] The heparan sulfate proteoglycan syndecan-1 regulates FGF binding and activity.
    Filla, MS
    Dam, P
    Rapraeger, AC
    MOLECULAR BIOLOGY OF THE CELL, 1996, 7 : 1073 - 1073
  • [35] Disruption of the Syndecan-1/Integrin Axis is a Novel Target for Myeloma Therapy
    Yang, Y.
    Ritchie, J. P.
    Ell, B.
    Rapraeger, A. C.
    Sanderson, R. D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S64 - S64
  • [36] Role of syndecan-1 in TRAIL-induced apoptosis in myeloma cells
    Wu, Yung-Hsuan
    Yang, Chen-Ying
    Chien, Wen-Li
    Lin, Kuo-I
    Lai, Ming-Zong
    JOURNAL OF IMMUNOLOGY, 2012, 188
  • [37] Transcriptional regulation of syndecan-1 expression by growth factors
    Jaakkola, P
    Jalkanen, M
    PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 63, 2000, 63 : 109 - 138
  • [38] Serum syndecan-1: a new independent prognostic marker in multiple myeloma
    Seidel, C
    Sundan, A
    Hjorth, M
    Turesson, I
    Dahl, IMS
    Abildgaard, N
    Waage, A
    Borset, M
    BLOOD, 2000, 95 (02) : 388 - 392
  • [39] The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
    Yang, Yang
    MacLeod, Veronica
    Dai, Yuemeng
    Khotskaya-Sample, Yekaterina
    Shriver, Zachary
    Venkataraman, Ganesh
    Sasisekharan, Ram
    Naggi, Annamaria
    Torri, Giangiacomo
    Casu, Benito
    Vlodavsky, Israel
    Suva, Larry J.
    Epstein, Joshua
    Yaccoby, Shmuel
    Shaughnessy, John D., Jr.
    Barlogie, Bart
    Sanderson, Ralph D.
    BLOOD, 2007, 110 (06) : 2041 - 2048
  • [40] Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells
    S Lamorte
    S Ferrero
    S Aschero
    L Monitillo
    B Bussolati
    P Omedè
    M Ladetto
    G Camussi
    Leukemia, 2012, 26 : 1081 - 1090
12345